Scarica l'app Stockscreener
21.71
5.10%
-1.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$22.93
Aprire:
$22.09
Volume 24 ore:
348.89K
Relative Volume:
0.10
Capitalizzazione di mercato:
$16.14B
Reddito:
$220.00K
Utile/perdita netta:
$-746.08M
Rapporto P/E:
-21.55
EPS:
-1.0074
Flusso di cassa netto:
$-211.81M
1 W Prestazione:
-2.38%
1M Prestazione:
+14.89%
6M Prestazione:
-16.72%
1 anno Prestazione:
+7.46%
Intervallo 1D:
$21.20
$22.20
Intervallo di 1 settimana:
$21.14
$25.49
Portata 52W:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
21.73 | 15.86B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.57 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.83 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.78 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.22 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
317.60 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire
Will Summit Therapeutics Inc. stock continue dividend increasesQuarterly Risk Review & Real-Time Buy Zone Alerts - newser.com
Summit Therapeutics Inc. stock momentum explainedJuly 2025 Review & High Conviction Investment Ideas - newser.com
Can Summit Therapeutics Inc. hit a new high this monthBuy Signal & Accurate Entry/Exit Alerts - newser.com
Statistical indicators supporting Summit Therapeutics Inc.’s strengthBear Alert & Growth Focused Investment Plans - newser.com
Will Summit Therapeutics Inc. stock gain from lower inflationJuly 2025 Chart Watch & Weekly Watchlist for Hot Stocks - newser.com
What drives Summit Therapeutics Inc stock priceSector Performance Drivers & Rapid Capital Portfolio - earlytimes.in
APEIRON CAPITAL Ltd Takes $25.56 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Automated trading signals detected on Summit Therapeutics Inc.IPO Watch & Stepwise Entry and Exit Trade Signals - newser.com
Summit Therapeutics stock reaffirmed Buy at UBS ahead of ESMO data - Investing.com
Has Summit Therapeutics Inc. formed a bullish divergenceWeekly Investment Recap & Consistent Return Investment Signals - newser.com
Positive Outlook for Summit Therapeutics Driven by Anticipated HARMONi-6 Trial Success - TipRanks
Is Summit Therapeutics Inc. stock supported by strong cash flowsGold Moves & Low Drawdown Momentum Trade Ideas - newser.com
Summit Therapeutics' (SMMT) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Where is Summit Therapeutics (SMMT) Headed According to Analysts? - Yahoo Finance
Public Employees Retirement System of Ohio Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Inc. (SMMT) Stock Analysis: Unveiling a 51.75% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
How to use Fibonacci retracement on Summit Therapeutics Inc.Gap Up & Community Verified Trade Signals - newser.com
1 Monster Stock in the Making to Buy and Hold - Yahoo Finance
Published on: 2025-10-05 07:31:28 - newser.com
How to monitor Summit Therapeutics Inc. with trend dashboards2025 Market Sentiment & Community Driven Trade Alerts - newser.com
How the European Spotlight on Ivonescimab’s Phase III Data Could Shape Summit Therapeutics (SMMT) - simplywall.st
Is Summit Therapeutics Inc. forming a bottoming baseJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance
H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - MSN
Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence - Benzinga
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo
Summit Therapeutics (NASDAQ:SMMT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Published on: 2025-09-30 03:00:28 - newser.com
Summit Therapeutics Shares Tumble As Lung Cancer Drug Disappoints Abroad - Finimize
Published on: 2025-09-30 00:09:58 - newser.com
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
What analysts say about Summit Therapeutics Inc stockResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):